Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
AssigneeInbiomotion S.L.
InventorsRoger Gomis, Joël Jean-Mairet
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
Claims24
A method for typing a sample of a subject suffering from prostate cancer, and treating said subject to inhibit metastasis or recurrence and/or to avoid, inhibit, and/or treat bone degradation, comprising:
- (i) quantifying the expression level, copy number, or amplification of the c-MAF gene in a prostate tumor sample;
- (ii) typing said prostate tumor sample by comparing the quantified expression level, copy number, or amplification of c-MAF to a predetermined reference level of c-MAF expression;
- (iii) determining that said typing indicates a risk of bone metastasis in said subject;
- and
- (iv) administering a therapeutically effective amount of a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of a c-MAF inhibitor, an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting, and/or treating bone degradation to said subject.
An in vitro method for designing a customized therapy for a subject having prostate cancer with bone metastasis which comprises
- (i) quantifying the c-MAF gene expression level, copy number, or amplification in a bone metastatic tumor tissue sample of said subject;
- (ii) comparing the expression level, copy number, or amplification obtained in step (i) with the expression level, copy number, or amplification of the c-MAF gene in a control sample, wherein an increase in the expression level, copy number, or amplification of the c-MAF gene in the tumor tissue sample is increased with respect to the expression level, copy number, or amplification of the c-MAF gene in the control sample, then said subject is susceptible to receive a therapy intended to prevent or inhibit bone degradation;
- (iii) determining that the subject has an increase in the expression level, copy number or amplification of the c-MAF gene in the tumor tissue sample with respect to the expression level, copy number or amplification of the c-MAF gene in the control sample;
- and
- (iv) administering a therapy intended to prevent or inhibit bone degradation.
A method for typing a sample of a subject suffering from prostate cancer, and treating said subject to avoid, inhibit, and/or treat bone degradation, comprising:
- (i) quantifying the expression level of c-MAF in a prostate tumor sample;
- (ii) typing said prostate tumor sample by comparing the quantified c-MAF expression level to a predetermined reference level of c-MAF expression level;
- (iii) determining that the typing indicates a risk of bone metastasis in said subject;
- and
- (iv) administering a therapeutically effective amount of clodronate or zoledronic acid to said subject.
Dependencies are inferred from the claim text.